What is the intrinsic value of Atara?
As of 2025-09-17, the Intrinsic Value of Atara Biotherapeutics Inc (ATRA) is
10.68 USD. This Atara valuation is based on the model Peter Lynch Fair Value.
With the current market price of 11.51 USD, the upside of Atara Biotherapeutics Inc is
-7.20%.
Is Atara undervalued or overvalued?
Based on its market price of 11.51 USD and our intrinsic valuation, Atara Biotherapeutics Inc (ATRA) is overvalued by 7.20%.
10.68 USD
Intrinsic Value
Atara Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(844.66) - (83.28) |
(128.43) |
-1215.8% |
| DCF (Growth 10y) |
(87.26) - (832.11) |
(133.14) |
-1256.7% |
| DCF (EBITDA 5y) |
(113.39) - (197.12) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(96.25) - (211.45) |
(1,234.50) |
-123450.0% |
| Fair Value |
10.68 - 10.68 |
10.68 |
-7.20% |
| P/E |
18.33 - 24.43 |
20.68 |
79.7% |
| EV/EBITDA |
54.27 - 174.70 |
83.39 |
624.5% |
| EPV |
(145.18) - (513.94) |
(329.56) |
-2963.2% |
| DDM - Stable |
8.11 - 36.70 |
22.41 |
94.7% |
| DDM - Multi |
(121.72) - (436.54) |
(191.37) |
-1762.6% |
Atara Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
80.80 |
| Beta |
0.46 |
| Outstanding shares (mil) |
7.02 |
| Enterprise Value (mil) |
104.12 |
| Market risk premium |
4.60% |
| Cost of Equity |
8.57% |
| Cost of Debt |
25.88% |
| WACC |
14.22% |